IPSC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 16:00):

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies...

Stats
Today's Volume	69 151.00
Average Volume	191 868
Market Cap	256.00M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.500 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.390
ATR14	$0.0190 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Russotti Gregory	Sell	5 000	Common Stock
2024-05-03	Carr Douglas	Sell	257	Common Stock
2024-05-03	Farid Adrienne	Sell	913	Common Stock
2024-04-22	Russotti Gregory	Sell	5 000	Common Stock
2024-03-07	Pfeiffenberger Brent	Buy	17 425	Common Stock

INSIDER POWER
69.62
Last 96 transactions
Buy: 10 700 785 \| Sell: 13 077 886

Volume Correlation

Long: 0.06 (neutral)

Short: 0.06 (neutral)

Signal:(51.208) Neutral

Century Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Century Therapeutics, Correlation - Currency/Commodity

0.25
( neutral )

0.06
( neutral )

0.00
( neutral )

-0.11
( neutral )

0.74
( moderate )

-0.10
( neutral )

Century Therapeutics, Financials

Annual	2023
Revenue:	$2.24M
Gross Profit:	$-10.81M (-483.62 %)
EPS:	$-2.30

FY	2023
Revenue:	$2.24M
Gross Profit:	$-10.81M (-483.62 %)
EPS:	$-2.30

FY	2022
Revenue:	$5.20M
Gross Profit:	$-4.87M (-93.71 %)
EPS:	$-2.27

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.759

Financial Reports:

No articles found.

Century Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Century Therapeutics,

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.